LAVAL, QC, July 25 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS;
NASDAQ: DDSS) today announced that it will host a conference call on
Friday, August 8 at 8:30 a.m. (ET) to discuss its second quarter 2008
financial results. Labopharm will report its second quarter 2008 financial
results via news release at approximately 7:00 a.m. the same day.

To access the conference call by telephone, dial 416-646-3095 or
1-800-814-4859. Please connect approximately 15 minutes prior to the
beginning of the call to ensure participation. The conference call will be
archived for replay until Friday, August 15, 2008 at midnight. To access
the archived conference call, dial 416-640-1917 or 1-877-289-8525 and enter
the reservation number 21278611 followed by the number sign.

A live audio webcast of the conference call will be available at
http://www.labopharm.com. Please connect at least 15 minutes prior to the
conference call to ensure adequate time for any software download that may
be required to join the webcast. The webcast will be archived at the above
web site for 30 days.

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of
existing small molecule drugs using its proprietary controlled-release
technologies. The Company's lead product, a unique once-daily formulation
of tramadol, is being commercially launched in key markets globally. The
Company also has a robust pipeline of follow-on products in both
pre-clinical and clinical development. Labopharm's vision is to become an
integrated, international, specialty pharmaceutical company with the
capability to internally develop and commercialize its own products. For
more information, please visit http://www.labopharm.com.

This press release contains forward-looking statements, which reflect
the Company's current expectations regarding future events. The
forward-looking statements involve risks and uncertainties. Actual events
could differ materially from those projected herein and depend on a number
of factors, including the uncertainties related to the regulatory process
in various countries for the approval of the Company's products and the
successful commercialization of the products throughout the world if they
are approved. Investors should consult the Company's ongoing quarterly
filings and annual reports for additional information on risks and
uncertainties relating to these forward-looking statements. The reader is
cautioned not to rely on these forward-looking statements. The Company
disclaims any obligation to update these forward-looking statements.

(Date:12/9/2016)... ... December 09, 2016 , ... MEDI+SIGN®, a provider of ... a new solution for Emergency Departments (ED) has been added to their portfolio. ... Department examination rooms, and with a simplified pallet of information available to the ...

(Date:12/8/2016)... ... December 08, 2016 , ... The West Virginia Medical Institute ... The name change aligns the entire company with its existing Quality Insights ... , “We are very proud of the achievements associated with the West Virginia ...

(Date:12/8/2016)... ... December 08, 2016 , ... Russ DiGilio , ... first national #QuackGivesBack campaign which supported local breast cancer organizations during National Breast ... Quack Gives Back initiative, and we’re very pleased with the participation in ...